New Alzheimers blood test could be a ‘game-changer’
LONDON: The elderly have helped to confirm a simple blood test to detect the earliest stages of Alzheimer’s works, paving the way for prevention of the most common type of dementia.
University of Melbourne’s Professor Chris Rowe, who is also the director of the Australian Dementia Network (ADNeT), recently returned from two conferences in America where the results of studies in 400 Melbourne patients with memory problems were presented.
The studies by ADNeT researchers at the Florey Institute, University of Melbourne, Austin Health and CSIRO showed the new pTau217 blood tests were 90 per cent accurate for the diagnosis of Alzheimer’s disease.
These blood tests are not yet commercially available, but are being trialled by ADNeT researchers with people attending memory specialist clinics in Melbourne, Sydney and Hobart and in selected primary care locations to confirm their value in routine specialist and primary care practice.
The test looks for a protein called tau in the blood, which can cause Alzheimer’s.
Professor Rowe said tau started to build up in the brain about 10 to 15 years before symptoms started showing. Amyloid plaques appear five to 10 years earlier than that and appear to drive the build-up of tau.
It comes as a Swedish team from the University of Gothenburg revealed overnight the results of an exciting study using a commercially available blood test to detect the earliest stages of Alzheimer’s.
These results have been celebrated as having the potential to “revolutionise diagnosis” for people with suspected Alzheimer’s.
The Swedish study was of people in their fifties, sixties and seventies and the test allowed researchers to assess whether participants were very likely or very unlikely to develop Alzheimer’s, or whether they fell somewhere in between and would need more invasive testing.
The study reported the test could detect the presence of tau proteins with an accuracy of up to 97 per cent.
It was published in the journal JAMA Neurology and examined 768 participants with an average age of 66, comparing the results of a blood test to those from cerebrospinal fluid taken via a lumbar puncture.
The blood was not collected via a finger prick, but the researchers are looking to see if this might be possible in future
Professor Rowe said these results confirmed the results from the Melbourne study.
“The combination of earlier detection of Alzheimer’s disease with the new blood tests and treatment with the new anti-amyloid antibodies offers the real prospect of reducing dementia in this country,” he said.
Professor Rowe said these blood tests were an exciting breakthrough and a “game-changer” that could be added to the tools to help prevent or treat Alzheimer’s that would also include new anti-amyloid drugs to stop the disease progressing.






